Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Cash Flow (2016 - 2026)

Aytu Biopharma has reported Net Cash Flow over the past 15 years, most recently at -$2.6 million for Q4 2025.

  • Quarterly Net Cash Flow fell 998.28% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, up 1007.83% year-over-year, with the annual reading at $10.9 million for FY2025, 467.44% up from the prior year.
  • Net Cash Flow was -$2.6 million for Q4 2025 at Aytu Biopharma, down from $1.7 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $12.8 million in Q2 2025 and troughed at -$9.3 million in Q3 2021.
  • The 5-year median for Net Cash Flow is -$310000.0 (2023), against an average of -$881789.5.
  • The largest YoY upside for Net Cash Flow was 5094.72% in 2025 against a maximum downside of 1063.2% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$5.3 million in 2021, then rose by 18.19% to -$4.3 million in 2022, then skyrocketed by 89.94% to -$435000.0 in 2023, then skyrocketed by 166.67% to $290000.0 in 2024, then plummeted by 998.28% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Cash Flow are -$2.6 million (Q4 2025), $1.7 million (Q3 2025), and $12.8 million (Q2 2025).